[ad_1]
Duopharma Biotech, one of Malaysia’s largest pharmaceutical companies, is committed to expanding access to a mobile breast cancer screening device at the community level.
It has signed a distribution agreement with the Malaysian unit of US femtech company UE LifeSciences to make the iBreastExam device available in primary care clinics across the country.
iBreastExam is a radiation-free, handheld device that uses DCPC (Dynamic Co-Planar Capacitive) sensor technology to measure breast tissue elasticity difference in real time at the point of care. This user-friendly device, which requires minimal training, can identify and sort clinically relevant breast masses in asymptomatic patients, as well as automate and standardize clinical breast examinations. It also stores data in the cloud, facilitating seamless tracking.
The accuracy of the device in the initial detection of breast cancer has been verified by several independent clinical studies around the world. EU LifeSciences has received various regulatory approvals in over 12 countries for iBreastExamincluding US FDA clearance and Europe CE mark.
WHY IS IT IMPORTANT
In Malaysia, almost 40% of new cases of breast cancer diagnosed each year were discovered at a very advanced stage. The five-year survival rate is nearly 60% for stage 3 cases and 23% for stage 4 cases.
These alarming figures, according to Duopharma Biotech, highlight the need for early detection of breast cancer. By distributing iBreastExam devices to primary care clinics through partnerships with private and public health organizations, the company seeks to address the lack of access to breast cancer detection and promote early community screening.
THE GREAT TREND
Cancer early detection initiatives around the world are now leveraging AI to further identify potential cases. South Korean medical AI company Lunit enables such large-scale programs, including New South Wales BreastScreen program in Australia and breast cancer screening in Capio S:t Göran Hospitalone of Sweden’s largest healthcare providers.
REGISTRATION
“There are still too many people in the community who don’t get regular screenings and only see a doctor if they have a serious complaint, which may be too late for effective treatment. So, by partnering with Duopharma Marketing with UE LifeSciences to distribute their mobile breast screening device to front-line healthcare providers in the community, we hope to increase access to preliminary screening and ultimately encourage Malaysian women to schedule comprehensive regular screenings, to improve their lives in the longer term,” said Leonard Ariff Abdul Shatar, CEO of Duopharma Biotech Group.
[ad_2]
Source link
